Solid Tumor Clinical Trial
— R-2Official title:
Effect of Refnot on Immunity in Cancer Patients
NCT number | NCT05898451 |
Other study ID # | R-2 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 4, 2009 |
Est. completion date | November 2011 |
Verified date | May 2023 |
Source | Refnot-Pharm Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study was planned to include disseminated patients with various solid tumors (melanoma, soft tissue sarcoma, breast cancer, colon cancer, etc.). The study drug was administered subcutaneously at a dose of 400,000 IU once a day, 3 times a week (every other day), for 4 weeks. In the absence of disease progression - an additional 4 weeks.
Status | Completed |
Enrollment | 55 |
Est. completion date | November 2011 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients who have exhausted standard methods of treatment. - Morphological (histological or cytological) confirmation of the diagnosis. - Age no more than 75 years. - General condition 0-2 (WHO). - Estimated life expectancy of at least 3 months. - Consent to treatment under this protocol. - The number of granulocytes is more than 2000/mm, platelets are more than 150000/mm. - The level of creatinine should not exceed 1.5 norms, liver enzymes (ALT, AST and alkaline phosphatase) should not exceed 3 norms. - For common disease, patients should receive standard treatment earlier. Exclusion Criteria: - Severe manifestations of cardiovascular diseases in the past and at present (myocardial infarction, hypertension, stroke, phlebothrombosis, coronary insufficiency requiring drug control, etc.). - Peptic ulcer of the stomach, duodenal ulcer (in the acute phase), uncorrected diabetes mellitus. - Mental illness preventing understanding of the treatment plan. - Pregnancy. - Metastases of a malignant tumor in the brain (according to clinical data). - Chronic use of corticosteroids or immunosuppressants. - Various neurological diseases that prevent this treatment. - Known allergic reactions and/or other significant allergic conditions. - Any immunotherapy within the last 6 weeks prior to enrollment in the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Refnot-Pharm Ltd |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the level of CD3+-cells | An increase in the level of CD3+-cells relative to the initial | 4 weeks | |
Primary | Change in the level of CD4+-cells | An increase in the level of CD4+-cells relative to the initial | 2 weeks | |
Primary | Change in the level of CD4+-cells | An increase in the level of CD4+-cells relative to the initial | 4 weeks | |
Primary | Change in the level of CD8+-cells | An increase in the level of T-lymphocytes relative to the initial one in those patients in whom it was reduced | 2 weeks | |
Primary | Change in the level of CD8+-cells | A decrease in the level of T-lymphocytes relative to the initial one in those patients in whom it was elevated | 2 weeks | |
Primary | Change in the ratio of CD4+/CD8+ | Increase in the ratio of lymphocytes / lymphocytes relative to the initial | 2 weeks | |
Primary | Change in the ratio of CD4+/CD8+ | Increase in the ratio of lymphocytes / lymphocytes relative to the initial | 4 weeks | |
Primary | Change in NK-cell activity | Increased activity of NK cells in patients with an initially reduced rate | 4 weeks | |
Primary | Change in NK-cell activity | Percentage increase in NK cell activity in patients with initially normal values | 2 weeks | |
Primary | Change in NK-cell activity | Percentage increase in NK cell activity in patients with initially normal values | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |